Literature DB >> 20217483

Thyroid cancer is the most common cancer associated with acromegaly.

Bennur Esen Gullu1, Ozlem Celik, Nurperi Gazioglu, Pinar Kadioglu.   

Abstract

The aim of the study was to screen the malignancy in an acromegalic patient group and to determine whether there was any increased risk and the incidence of malignancy and its association with disease characteristics such as duration of disease, latency in diagnosis, and GH and IGF-1 levels. One hundred-five (65 female, 40 male) patients with acromegaly followed and treated at Cerrahpasa Medical School, Endocrinology and Metabolism outpatient clinic between 1983 and 2007 were included in this study. The patients were screened with colonoscopy, mammography, and thyroid and prostate ultrasonography (US). Malignancy was detected in 16 (15%) patients. Thyroid cancer was found in 5 patients (4.7%), breast cancer in 3 (2.8%), colon cancer in 2 (1.9%), lung cancer in 2 (1.9%), cervix cancer in 1 (0.9%), myelodysplastic syndrome (MDS) in 1 (0.9%), cholangiocarcinoma in 1 (0.9%), and multiple endocrine neoplasm (MEN) type 1 in 1 patient (0.9%). Cancer was more common in the male patients (P = 0.046) and high levels of GH increased the risk of cancer development (P = 0.046). In this series, the most commonly detected cancer types were thyroid followed by breast and colon cancers. Although high levels of initial GH seemed to increase the risk of cancer development in acromegalic patients, age, gender, age at the time of diagnosis, duration of disease, and initial IGF-I levels were not associated with cancer development.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20217483     DOI: 10.1007/s11102-010-0224-9

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  44 in total

1.  The effects of autocrine human growth hormone (hGH) on human mammary carcinoma cell behavior are mediated via the hGH receptor.

Authors:  K K Kaulsay; T Zhu; W Bennett; K O Lee; P E Lobie
Journal:  Endocrinology       Date:  2001-02       Impact factor: 4.736

Review 2.  Does growth hormone cause cancer?

Authors:  P J Jenkins; A Mukherjee; S M Shalet
Journal:  Clin Endocrinol (Oxf)       Date:  2006-02       Impact factor: 3.478

Review 3.  Unwanted effects of growth hormone excess in the adult.

Authors:  S Melmed
Journal:  J Pediatr Endocrinol Metab       Date:  1996-06       Impact factor: 1.634

4.  A pooled analysis of case-control studies of thyroid cancer. IV. Benign thyroid diseases.

Authors:  S Franceschi; S Preston-Martin; L Dal Maso; E Negri; C La Vecchia; W J Mack; A McTiernan; L Kolonel; S D Mark; K Mabuchi; F Jin; G Wingren; R Galanti; A Hallquist; E Glattre; E Lund; F Levi; D Linos; E Ron
Journal:  Cancer Causes Control       Date:  1999-12       Impact factor: 2.506

5.  Benign and malignant tumors in patients with acromegaly.

Authors:  J Barzilay; G J Heatley; G W Cushing
Journal:  Arch Intern Med       Date:  1991-08

6.  Free insulin-like growth factor-I and breast cancer risk.

Authors:  B D Li; M J Khosravi; H J Berkel; A Diamandi; M A Dayton; M Smith; H Yu
Journal:  Int J Cancer       Date:  2001-03-01       Impact factor: 7.396

7.  Review of thyroid cancer cases among patients with previous benign thyroid disorders.

Authors:  G From; A Mellemgaard; N Knudsen; T Jørgensen; H Perrild
Journal:  Thyroid       Date:  2000-08       Impact factor: 6.568

Review 8.  Acromegaly pathogenesis and treatment.

Authors:  Shlomo Melmed
Journal:  J Clin Invest       Date:  2009-11-02       Impact factor: 14.808

9.  An association between acromegaly and thyroid carcinoma.

Authors:  C Balkany; G W Cushing
Journal:  Thyroid       Date:  1995-02       Impact factor: 6.568

10.  Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia.

Authors:  C S Mantzoros; A Tzonou; L B Signorello; M Stampfer; D Trichopoulos; H O Adami
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more
  34 in total

Review 1.  Risk of Neoplasia in Pediatric Patients Receiving Growth Hormone Therapy--A Report From the Pediatric Endocrine Society Drug and Therapeutics Committee.

Authors:  Sripriya Raman; Adda Grimberg; Steven G Waguespack; Bradley S Miller; Charles A Sklar; Lillian R Meacham; Briana C Patterson
Journal:  J Clin Endocrinol Metab       Date:  2015-04-03       Impact factor: 5.958

Review 2.  Complications of acromegaly: thyroid and colon.

Authors:  Amit Tirosh; Ilan Shimon
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

Review 3.  The changing face of acromegaly--advances in diagnosis and treatment.

Authors:  Antônio Ribeiro-Oliveira; Ariel Barkan
Journal:  Nat Rev Endocrinol       Date:  2012-06-26       Impact factor: 43.330

4.  Increased thyroid cancer risk in acromegaly.

Authors:  Selcuk Dagdelen; Nese Cinar; Tomris Erbas
Journal:  Pituitary       Date:  2014-08       Impact factor: 4.107

Review 5.  Acromegaly: clinical features at diagnosis.

Authors:  Lucio Vilar; Clarice Freitas Vilar; Ruy Lyra; Raissa Lyra; Luciana A Naves
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

Review 6.  Medical therapy of acromegaly in Turkey.

Authors:  O Celik; P Kadioglu
Journal:  J Endocrinol Invest       Date:  2010-09       Impact factor: 4.256

7.  A novel germline mutation in the aryl hydrocarbon receptor-interacting protein (AIP) gene in an Italian family with gigantism.

Authors:  C Urbani; D Russo; F Raggi; M Lombardi; C Sardella; I Scattina; I Lupi; L Manetti; L Tomisti; C Marcocci; E Martino; F Bogazzi
Journal:  J Endocrinol Invest       Date:  2014-07-05       Impact factor: 4.256

8.  Evaluation of thyroid diseases and differentiated thyroid cancer in acromegalic patients.

Authors:  Serkan Dogan; Aysegul Atmaca; Selcuk Dagdelen; Belkis Erbas; Tomris Erbas
Journal:  Endocrine       Date:  2013-05-14       Impact factor: 3.633

9.  Increased risk of preneoplastic colonic lesions and colorectal carcinoma in acromegaly: multicenter case-control study.

Authors:  Maria Florencia Battistone; Karina Miragaya; Amelia Rogozinski; Monica Agüero; Analia Alfieri; Maria Carolina Ballarino; Laura Boero; Karina Danilowicz; Sabrina Diez; Marina Donoso; Patricia Fainstein-Day; Alejandra Furioso; Natalia Garcia-Basavilbaso; Mariela Glerean; Debora Katz; Monica Loto; Susana Mallea-Gil; Marcela Martinez; Maria Isabel Sabate; Marisa Servidio; Patricia Slavinsky; Graciela Stalldecker; Soledad Sosa; Grabriela Szuman; Julieta Tkatch; Ignacio Caldo; Daniela Lubieniecki; Mirtha Guitelman
Journal:  Pituitary       Date:  2020-10-15       Impact factor: 4.107

10.  The role of insulin-like growth factor 1 in the development of benign and malignant thyroid nodules.

Authors:  Engin Baştürk; Metin Kement; Dilek Yavuzer; Selahattin Vural; Cem Gezen; Hülya Ilıksu Gözü; Ayşe Karadayı; Mustafa Oncel
Journal:  Balkan Med J       Date:  2012-06-01       Impact factor: 2.021

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.